Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trovafloxacin

Drug Profile

Trovafloxacin

Alternative Names: CP-99,219; Trovafloxacin mesylate; Trovan; Turvel

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antibacterials; Fluoroquinolones; Naphthyridines
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Bacterial infections; Genital tract infections
  • Market Withdrawal Respiratory tract infections
  • Discontinued Toxoplasmosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 20 Mar 2001 The European Commission has formally withdrawn the marketing authorisations in the European Union for trovafloxacin and alatrofloxacin
  • 20 Mar 2001 Withdrawn for Bacterial infections in European Union (PO), including Austria, Denmark, Finland, The Netherlands, Portugal and Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top